Free tool
Cell therapy stocks
We cover 6 companies grouped under the Cell therapy theme. The median market value in the group is $32.80M. Across the group, the median move over the past trading day is +0.86%. Price change over the past year runs from −55.8% to +27.9% across the middle 80 percent of the group, with a median of −38.3%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
6 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| V3V.DE | FamiCord AG | $58.74M | Micro cap | −61.35% |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | $54.52M | Micro cap | +70.43% |
| PTG.WA | Poltreg S.A. | $34.78M | Micro cap | −14.68% |
| PSH0.DE | Sernova Biotherapeutics Inc | $30.82M | Micro cap | −27.68% |
| F98.F | CytoMed Therapeutics Limited | $10.76M | Micro cap | −50.30% |
| BSFA.L | BSF Enterprise Plc | $3.03M | Micro cap | −48.89% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.